Selective Immunomodulation in MS
Introduction
MS: Potential for Multi-Cellular Autoimmune Pathogenesis
Genetic and Environmental Factors Contribute to the Development of MS
MS as a Result of Imbalanced Immune-Regulatory Networks
Therapeutic Approach 1: General Immunosuppression
Therapeutic Approach 2: Immunomodulation
Therapeutic Approach 3: Immune-Selective Intervention – Neutralization / Interference With Leukocyte Trafficking
Therapeutic Approach 4: Immune-Selective Intervention - Depletion
Depletion Strategies
Networks That Drive and Attenuate MS Pathophysiology
Immune Regulation Approaches
Defining IRT - The 3Rs
T & B Cell Dynamics
Maintenance Therapies vs IRTs
CLARITY Study: Efficacy of Cladribine in RRMS
CLARITY Study: Time to First Relapse and Progression
Efficacy of Alemtuzumab vs IFN-Beta as First-Line Treatment: Phase 3 Study
Cladribine Safety Profile
Alemtuzumab Safety Profile
Case Study IRT - PART 1 HSCT vs Alemtuzumab vs Cladribine
Case 1: Discussion
European Bone Marrow Transplantation (EBMT) Guidelines: HSCT Eligibility
Alemtuzumab: CARE-MS 5-Year Data
Alemtuzumab: CARE-MS 8-Year Data
Long-term Efficacy of Cladribine: CLARITY Extension Study
Cladribine: MS Patients With High Relapse Activity had Reduced Risk of EDSS Worsening
HSCT vs Continued DMT in Patients With RRMS
Long-Term Outcomes After HSCT in Patients With MS
Case Study IRT - PART 2 HSCT vs Alemtuzumab vs Cladribine
Cohort Study: Alemtuzumab vs Natalizumab
Cohort Study: Cladribine vs Natalizumab
Derisking Immunosuppression
Derisking Immunosuppression
Derisking Immunosuppression
Practical Implications of IRTs
Conclusion
Abbreviations
Abbreviations (cont)
Abbreviations (cont)
Abbreviations (cont)